{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:41:17Z","timestamp":1791348077965,"version":"4.3.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological and Toxicological Methods"],"published-print":{"date-parts":[[2005,7]]},"DOI":"10.1016\/j.vascn.2005.04.008","type":"journal-article","created":{"date-parts":[[2005,6,3]],"date-time":"2005-06-03T07:37:00Z","timestamp":1117784220000},"page":"146-153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":88,"title":["Estimation of potency of HERG channel blockers: Impact of voltage protocol and temperature"],"prefix":"10.1016","volume":"52","author":[{"given":"Jian-An","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyi","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Daharsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Atterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vascn.2005.04.008_bib1","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1469-7793.1998.333bh.x","article-title":"Modulation of human erg K+ channel gating by activation of a G protein-coupled receptor and protein kinase C","volume":"511","author":"Barros","year":"1998","journal-title":"Journal of Physiology"},{"key":"10.1016\/j.vascn.2005.04.008_bib2","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S1461-5347(99)00172-8","article-title":"QT interval prolongation by non-cardiovascular drugs: Issues and solutions for novel drug development","volume":"2","author":"Crumb","year":"1999","journal-title":"Pharmaceutical Science & Technology Today"},{"key":"10.1016\/j.vascn.2005.04.008_bib4","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0022-3565(24)37646-3","article-title":"Blockade of HERG and Kv1.5 by ketoconazole","volume":"286","author":"Dumaine","year":"1998","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.vascn.2005.04.008_bib5","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1093\/emboj\/21.8.1889","article-title":"14-3-3 amplifies and prolongs adrenergic stimulation of HERG K+ channel activity","volume":"15","author":"Kagan","year":"2002","journal-title":"EMBO Journal"},{"key":"10.1016\/j.vascn.2005.04.008_bib6","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S1050-1738(00)00071-2","article-title":"Regulation of the cardiac repolarizing HERG potassium channel by protein kinase A","volume":"10","author":"Kiehn","year":"2000","journal-title":"Trends in Cardiovascular Medicine"},{"key":"10.1016\/j.vascn.2005.04.008_bib7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.vascn.2004.06.003","article-title":"Variability in the measurement of hERG potassium channel inhibition: Effects of temperature and stimulus pattern","volume":"50","author":"Kirsch","year":"2004","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2005.04.008_bib8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0014-2999(02)02074-5","article-title":"A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs","volume":"450","author":"Kongsamut","year":"2002","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.vascn.2005.04.008_bib9","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0014-5793(03)00662-8","article-title":"Preferential closed channel blockade of HERG potassium currents by chemically synthesised BeKm-1 scorpion toxin","volume":"547","author":"Milnes","year":"2003","journal-title":"FEBS Letters"},{"key":"10.1016\/j.vascn.2005.04.008_bib10","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0378-4274(01)00510-0","article-title":"Cardiotoxicity of new antihistamines and cisapride","volume":"127","author":"Paakkari","year":"2002","journal-title":"Toxicology Letters"},{"key":"10.1016\/j.vascn.2005.04.008_bib11","first-page":"303","article-title":"QT interval prolongation and cardiac risk assessment for novel drugs","volume":"4","author":"Picard","year":"2003","journal-title":"Current Opinion in Investigational Drugs"},{"key":"10.1016\/j.vascn.2005.04.008_bib12","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0014-5793(97)01249-0","article-title":"A mechanism for the pro arrhythmic effects of cisapride (Propulsid): High affinity blockade of the human cardiac potassium channel HERG","volume":"417","author":"Rampe","year":"1997","journal-title":"FEBS Letters"},{"key":"10.1016\/j.vascn.2005.04.008_bib14","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0008-6363(02)00846-5","article-title":"Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development","volume":"58","author":"Redfern","year":"2003","journal-title":"Cardiovascular Research"},{"key":"10.1016\/j.vascn.2005.04.008_bib13","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S0006-291X(03)00980-X","article-title":"Characterisation of recombinant HERG K+ channel blockade by the Class Ia antiarrhythmic drug procainamide","volume":"306","author":"Ridley","year":"2003","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.vascn.2005.04.008_bib15","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1161\/01.CIR.94.4.817","article-title":"Arrhythmias\/long QT: HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine","volume":"94","author":"Roy","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.vascn.2005.04.008_bib16","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1161\/01.RES.78.3.499","article-title":"Class III antiarrhythmic drugs block HERG, a human cardiac delayed rectifier K+ channel: Open channel block by methanesulfonanilides","volume":"78","author":"Spector","year":"1996","journal-title":"Circulation Research"},{"key":"10.1016\/j.vascn.2005.04.008_bib17","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0014-5793(96)00355-9","article-title":"Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole","volume":"385","author":"Suessbrich","year":"1996","journal-title":"FEBS Letters"},{"key":"10.1016\/j.vascn.2005.04.008_bib18","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0006-2952(98)00002-1","article-title":"Human ether-a-go-go related gene (HERG) K+ channels as pharmacological targets: Present and future implications","volume":"55","author":"Taglialatela","year":"1998","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.vascn.2005.04.008_bib20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejphar.2004.04.015","article-title":"Comparison of kinetic properties of quinidine and dofetilide block of HERG channels","volume":"493","author":"Tsujimae","year":"2004","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.vascn.2005.04.008_bib21","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1124\/jpet.302.1.320","article-title":"Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics","volume":"302","author":"Volberg","year":"2002","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.vascn.2005.04.008_bib22","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0008-6363(00)00155-3","article-title":"Comparative effects of azimilide and ambasilide on the human ether-a-go-go-related gene (HERG) potassium channel","volume":"48","author":"Walker","year":"2000","journal-title":"Cardiovascular Research"},{"key":"10.1016\/j.vascn.2005.04.008_bib23","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1111\/j.1572-0241.2001.03927.x","article-title":"Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and food and drug administration regulatory actions","volume":"96","author":"Wysowski","year":"2001","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.vascn.2005.04.008_bib24","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1540-8167.1997.tb00780.x","article-title":"Azimilide (NE-10064) can prolong or shorten the action potential duration in canine ventricular myocytes: Dependence on blockade of K, Ca, and Na channels","volume":"8","author":"Yao","year":"1997","journal-title":"Journal of Cardiovascular Electrophysiology"},{"key":"10.1016\/j.vascn.2005.04.008_bib25","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1016\/S0006-3495(03)70028-9","article-title":"BeKm-1 Is a HERG-specific toxin that shares the structure with ChTx but the mechanism of action with ErgTx1","volume":"84","author":"Zhang","year":"2003","journal-title":"Biophysical Journal"},{"key":"10.1016\/j.vascn.2005.04.008_bib26","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0006-3495(98)77782-3","article-title":"Properties of HERG channels stably expressed in HEK293 cells studied at physiological temperature","volume":"74","author":"Zhou","year":"1998","journal-title":"Biophysical Journal"}],"container-title":["Journal of Pharmacological and Toxicological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871905000560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871905000560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T23:51:03Z","timestamp":1761004263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056871905000560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["S1056871905000560"],"URL":"https:\/\/doi.org\/10.1016\/j.vascn.2005.04.008","relation":{},"ISSN":["1056-8719"],"issn-type":[{"value":"1056-8719","type":"print"}],"subject":[],"published":{"date-parts":[[2005,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estimation of potency of HERG channel blockers: Impact of voltage protocol and temperature","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological and Toxicological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vascn.2005.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}